Multiple myeloma can in rare cases cause a rash, although most rashes with multiple myeloma are due to infections and weakened immune systems and as a result of treatment side effects, however multiple myeloma itself rarely causes a direct skin rash, and affects less than 1 percent of people with multiple myeloma.
Many medications that are used to treat multiple myeloma commonly trigger skin rashes, which include:
Immunomodulatory drugs like lenalidomide (Revlimid) or thalidomide frequently cause dry, itchy, or maculopapular/morbilliform rashes.
Proteasome inhibitors like bortezomib (Velcade) can cause localized or generalized skin reactions.
Bispecific antibodies like talquetamab can also result in skin and nail changes.
Stem cell transplants and high-dose chemotherapy can lead to skin irritation or graft-versus-host disease (GVHD) if a donor transplant is used.
Also because multiple myeloma compromises the immune system, people with multiple myeloma are at a higher risk for infections that present with rashes.
Shingles (herpes zoster)—which appears as painful clusters of red blisters along a nerve path—is particularly common.
Fungal and bacterial skin infections can also occur.
In very rare cases, direct or systemic manifestations of the multiple myeloma disease or related proteins can cause dermatological conditions such as Cutaneous Manifestations of Multiple Myeloma - PMC - NIH:• AL amyloidosis.
Leukocytoclastic vasculitis.
Pyoderma gangrenosum.
Cutaneous plasmacytomas (tumors of plasma cells in the skin)
Urticaria (hives) or secondary skin cancers.
The most promising treatments for multiple myeloma are treatments such as CAR T-Cell Therapy, Bispecific T-Cell Engagers (BiTEs), Monoclonal and Multi-Drug Combinations, Antibody-Drug Conjugates (ADCs) and Emerging Oral CELMoDs and Novel Targets.
Emerging Oral CELMoDs and Novel Targets for multiple myeloma treatment include newer cereblon E3 ligase modulators (CELMoDs) like misigotamab and dual-targeting or trispecific antibodies are continuing to push remission windows further in clinical trials.
Antibody-Drug Conjugates (ADCs) for treating multiple myeloma include the use of targeted agents like belantamab mafodotin (Blenrep) deliver therapy directly into BCMA-expressing myeloma cells and are re-emerging strongly in effective combination regimens for relapsed disease.
Monoclonal and Multi-Drug Combinations for treating multiple myeloma include standard frontline and early-relapse care has shifted toward powerful quadruplet combinations (such as daratumumab added to proteasome inhibitors, immunomodulatory drugs, and dexamethasone), which significantly deepen minimal residual disease (MRD) negativity.
Bispecific T-Cell Engagers (BiTEs) for multiple myeloma include use of drugs like teclistamab (Tecvayli), elranatamab (Elrexfio), and talquetamab (Talvey) link a patient's T-cells directly to specific proteins (such as BCMA or GPRC5D) on myeloma cells to trigger an immune attack, showing high response rates even in heavily pre-treated or refractory patients.
CAR T-Cell Therapy for treating multiple myeloma include the use of personalized treatments—such as ciltacabtagene autoleucel (Carvykti) and idecabtagene vicleucel (ide-cel)—reengineer a patient's T-cells to target B-cell maturation antigen (BCMA) on myeloma cells. Long-term data show that treatment can keep a notable percentage of late-stage or relapsed patients cancer-free for extended periods.
While a universal, traditional cure for multiple myeloma does not yet exist, medical science has shifted from viewing it as an uniformly fatal disease to achieving functional cures for a growing subset of patients.
Current Progress Toward a Cure for multiple myeloma include:
Higher Long-Term Remission Rates:
Twenty-five years ago, only about 3% to 4% of patients achieved long-term remission.
Today, with modern multi-drug and immune therapies, 30% to 40% of patients experience deep, long-term remissions.
Extended Survival: Median overall survival with multiple myeloma now has jumped from roughly 3 years decades ago to 10 to 15 years or more today, and some intensively treated patients are living treatment-free for over a decade.
The "Functional Cure" Concept:
Oncologists increasingly talk about an operative or functional cure—where patients with multiple myeloma now live a normal or near-normal lifespan without active symptoms or continuous treatment, even if tiny residual cells may remain.
Organizations like the International Myeloma Foundation note that a defined "cure fraction" is actively rising.